« Return to News | Awards & Advancement

Medrio appoints execs from Genentech and NetSuite to board of directors

Thursday, November 15, 2012 08:00 AM

Medrio, a provider of advanced eClinical software as a service (SaaS) for clinical research, has made key appointments to its board of directors: Richard H. Scheller, executive vice president of research at Genentech, and Dave Lipscomb, founder and former executive at NetSuite.

Scheller is responsible for setting the strategy for Genentech’s research and drug discovery activities, is a member of Genentech’s executive committee, and is a member of the Roche Enlarged Corporate Executive Committee. Prior to joining Genentech, he served as professor of molecular and cellular physiology at Stanford University and as an investigator with the Howard Hughes Medical Institute.

Lipscomb brings great depth in software as a service (SaaS) to Medrio after spending 14 years at NetSuite since its inception in 1998. Holding the titles senior vice president of engineering, chief information officer and senior vice president of customer loyalty, he drove engineering, product management and IT operations. Prior to joining NetSuite, Lipscomb founded mBED Software and was a director in Oracle’s New Media Division. He has been building client/server and web server software products for 20 years.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.